David T. Rubin, MD, FACG

Poster(s):

• P1637 - Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies

  Monday, October 25, 2021

  10:30 AM – 4:15 PM PT

• P1638 - Upadacitinib Is Effective at Inducing Clinical Remission and Response in Ulcerative Colitis Patients Regardless of Baseline Corticosteroid Use: Results From Two Phase 3 Studies

  Monday, October 25, 2021

  10:30 AM – 4:15 PM PT

• P1639 - Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Conditions Treated With Systemic Immunosuppressive Therapies: A Population-Based Study

  Monday, October 25, 2021

  10:30 AM – 4:15 PM PT

• P1640 - Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies

  Monday, October 25, 2021

  10:30 AM – 4:15 PM PT

• P1641 - Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study

  Monday, October 25, 2021

  10:30 AM – 4:15 PM PT